Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $38,221.81 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the sale, the insider directly owned 614,887 shares in the company, valued at $3,178,965.79. This trade represents a 1.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $3,167.68.
• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.97, for a total value of $2,982.00.
• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $21,010.64.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded up $0.10 during midday trading on Tuesday, reaching $5.44. The stock had a trading volume of 284,563 shares, compared to its average volume of 187,273. The firm has a market capitalization of $456.36 million, a PE ratio of -10.46 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $2.92 and a 12 month high of $6.30. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The firm’s 50-day moving average price is $5.12 and its 200 day moving average price is $4.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $2,157,000. Royce & Associates LP bought a new position in shares of SOPHiA GENETICS in the fourth quarter worth approximately $2,009,000. Finally, Sei Investments Co. purchased a new stake in SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. 31.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.